Abstract
Two patients with proven 5-fluorouracil (5-FU)-associated cardiotoxicity were treated with the specific thymidylate synthase inhibitor raltitrexed safely, without evidence of cardiotoxicity. Raltitrexed might be an alternative for patients with advanced colorectal cancer and 5-FU-associated cardiotoxicity. 5-FU cardiotoxicity is not due to the antineoplastic mechanisms via thymidilate synthase.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Köhne, CH., Thuss-Patience, P., Friedrich, M. et al. Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity. Br J Cancer 77, 973–977 (1998). https://doi.org/10.1038/bjc.1998.160
Issue Date:
DOI: https://doi.org/10.1038/bjc.1998.160
- Springer Nature Limited
This article is cited by
-
An international survey of healthcare providers’ knowledge of cardiac complications of cancer treatments
Cardio-Oncology (2019)
-
5-Fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity
Cancer Chemotherapy and Pharmacology (2012)
-
Acute Coronary Syndrome Associated with Continuous 5-Fluorouracil Infusion in a Patient with Metastatic Colorectal Cancer—A Case Report with a Discussion on This Clinical Dilemma
Journal of Gastrointestinal Cancer (2009)
-
Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine
Cancer Chemotherapy and Pharmacology (2006)
-
Kardiotoxizit�t von 5-Flurouracil
Der Onkologe (2005)